Found: 5
Select item for more details and to access through your institution.
Safety and efficacy of Ovaleap<sup>®</sup> (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
- Published in:
- Reproductive Biology & Endocrinology, 2016, v. 14, p. 1, doi. 10.1186/s12958-016-0164-y
- By:
- Publication type:
- Article
Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f<sup>®</sup> in healthy women after follicle-stimulating hormone downregulation.
- Published in:
- Reproductive Biology & Endocrinology, 2015, v. 13, p. 1, doi. 10.1186/s12958-015-0124-y
- By:
- Publication type:
- Article
Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
- Published in:
- Reproductive Biology & Endocrinology, 2016, v. 14, p. 1, doi. 10.1186/s12958-015-0135-8
- By:
- Publication type:
- Article
Comment on "Biosimilar FSH preparations-are they identical twins or just siblings?".
- Published in:
- 2016
- By:
- Publication type:
- Letter to the Editor
Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap (XM17), Comparability with Gonal-f, and Performance/Consistency.
- Published in:
- Drugs in R&D, 2017, v. 17, n. 2, p. 305, doi. 10.1007/s40268-017-0182-z
- By:
- Publication type:
- Article